Publications: Dr Elizabeth Nally

Nally E, Lyon J, Regan M, Rini B, Voss M, Atkins MB, Powles T, McDermott DF ( 2026 ) . Is it time to reassess standard toxicity and patient reported outcomes methodologies for the adjuvant use of immune checkpoint inhibitors (ICIs)? . Annals of Oncology

Membribes SC, Berney DM, Beltran L, Nally E, Jackson-Spence F, Szabados B, Mariathasan S, Powles T et al. ( 2026 ) . HER1–HER4 expression and co-expression in advanced urothelial carcinoma . ESMO Open vol. 11 , ( 9 )

Jackson‐Spence F, Aspden D, Chauhan V, Diaz S, Graham C, Young M, Nally E, Wells JC et al. ( 2026 ) . Characteristics of Patients With Advanced or Metastatic Urothelial Cancer Unable to Complete Six Cycles Chemotherapy . Cancer Medicine vol. 15 , ( 6 )

Hussain SA, Carbonero IG, Cerrillo JM, Puente J, Borrega P, Malik J, Dourthe L-M, Jones R et al. ( 2026 ) . Comparison of cisplatin/gemcitabine or carboplatin/gemcitabine on efficacy, toxicity, and quality of life from the randomized DISCUS trial . Journal of Clinical Oncology vol. 44 , ( 16_suppl ) 4583 - 4583 .

Nally E, Kudva V, Sherpa G, Wang Y, Sordelli F, Basile G, Coca Membribes S, Graham C et al. ( 2026 ) . Decision regret and toxicity perception following adjuvant pembrolizumab in renal cell carcinoma . Journal of Clinical Oncology vol. 44 , ( 16_suppl ) 4512 - 4512 .

Coca Membribes S, Jackson-Spence F, Suárez C, Patel PM, Larkin JMG, Perez Valderrama B, Rodríguez-Vida A, Mendez Vidal MJ et al. ( 2026 ) . KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial . Journal of Clinical Oncology vol. 44 , ( 7_suppl ) 557 - 557 .

Graham C, Coca Membribes S, Wells JC, Nally E, Jackson-Spence F, Lalwani S, Szabados BE, Powles T ( 2026 ) . Patient and trial design factors influencing participation in prospective bladder and kidney cancer clinical trials . Journal of Clinical Oncology vol. 44 , ( 7_suppl ) 655 - 655 .

Nally E, Jovaisaite A, Coca Membribes S, Priyadarshini G, Graham C, MacDonald A, Jackson-Spence F, Szabados B et al. ( 2026 ) . VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis . Cancers vol. 18 , ( 5 )

Nally E, Sordelli F, Kudva V, Basile G, Hughes DJ, Boleti E, Powles TB, Bex A et al. ( 2025 ) . 165P Adjuvant pembrolizumab for early-stage renal cell carcinoma: A real-world experience from two UK tertiary oncology centers . Immuno-Oncology Technology vol. 28 ,

Shah K, Bergerot PG, Castro D, Mercier B, Nally E, Ali A, Hutson TE, Bex A et al. ( 2025 ) . 11Exploring Health-Related quality of life across the disease spectrum in renal cell carcinoma: a conceptual domain analysis . The Oncologist vol. 30 , ( Supplement_2 )

Wells JC, Membribes SC, Nally E, Jackson-Spence F, Lalwani SB, Graham C, Szabados BE, Powles TB ( 2025 ) . 3130eP Time commitment requirements for clinical trial participation in patients with metastatic urothelial carcinoma . Annals of Oncology vol. 36 ,

Bergerot CD, Cella D, Bergerot PG, Castro DV, Mercier BD, Nally E, Ali AA, Philip EJ et al. ( 2025 ) . Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma . European Urology Oncology vol. 8 , ( 5 ) 1295 - 1302 .

Membribes SC, Nally E, Jackson-Spence F, Graham C, Lalwani S, Szabados B, Powles T ( 2025 ) . Established and emerging biomarkers approaches in urothelial carcinoma . Expert Review of Anticancer Therapy vol. 25 , ( 11 ) 1235 - 1241 .

Nally E, Powles T ( 2025 ) . Perioperative durvalumab for muscle invasive bladder cancer: the start of a new chapter . Future Oncology vol. 21 , ( 20 ) 2561 - 2563 .

Bergerot CD, Bergerot PG, Castro DV, Mercier B, Nally E, Ali A, Hutson TE, Psutka SP et al. ( 2025 ) . Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC) . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 526 - 526 .

Nally E, Ainsworth G, Brown SR, Bergerot CD, Wells C, Young MN, Westerman T, Coca S et al. ( 2025 ) . Improving health related quality of life (HRQoL) assessment and immune related adverse event (irAE) classification with novel tools in renal cancer . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 525 - 525 .

Wells C, Nally E, Jackson-Spence F, Coca S ( 2025 ) . Systemic therapy clinical trial participation in patients with bladder and kidney cancers . Journal of Clinical Oncology vol. 43 , ( 5_suppl ) 451 - 451 .

Semaan K, Nawfal R, Janjigian YY, Robert C, Peters S ( 2024 ) . Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types . The Lancet Oncology vol. 26 , ( JAMA Netw Open 7 2024 ) 161 - 164 .

Nally E, Young M, Wells C, Fairhead R, Baines K, Cheney-Lowe H, Jackson-Spence F, Powles T ( 2024 ) . Is HER2 the New NECTIN4 in Advanced Urothelial Cancer? . European Urology Focus vol. 10 , ( 2 ) 219 - 221 .

Chauhan V, Diaz SS, Jara P, Efovi D, Gurung A, Young M, Wells C, Nally E et al. ( 2024 ) . Abstract B013: Novel prognostic score for patients with metastatic bladder cancer on immunotherapy . Clinical Cancer Research vol. 30 , ( 10_Supplement ) b013 - b013 .

Nally E, Young M, Chauhan V, Wells C, Szabados B, Powles T, Jackson-Spence F ( 2024 ) . Upper Tract Urothelial Carcinoma (UTUC): Prevalence, Impact and Management Challenge . Cancer Management and Research vol. 16 , ( 0 ) 467 - 475 .

Young M, Tapia JC, Szabados B, Jovaisaite A, Jackson-Spence F, Nally E, Powles T ( 2024 ) . NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors . Clinical Genitourinary Cancer vol. 22 , ( 3 )

Diaz SS, Chauhan V, Gurung A, Nally E, Young M, Wells C, Jackson-Spence F, Szabados B et al. ( 2024 ) . A0745 Analysing resistance and progression patterns to immune checkpoint inhibitors in urothelial carcinoma . European Urology vol. 85 ,

Bergerot CD, Castro DV, Bergerot PG, Mercier BD, Nally E, Ali AA, Philip EJ, Buso M et al. ( 2024 ) . Development of a patient-centered health-related quality of life (HRQOL) measure for metastatic renal cell carcinoma (mRCC): A three-phase study . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 365 - 365 .

Jackson-Spence F, Chauhan V, Silva Diaz S, Gurung A, Young MN, Nally E, Wells C, Szabados B et al. ( 2024 ) . Identification of patients with metastatic urothelial cancer not able to receive maintenance avelumab . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 702 - 702 .

Young MN, Szabados B, Assaf Z, Jackson-Spence F, Nally E, Wells C, Suárez C, Castellano D et al. ( 2024 ) . Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial . Journal of Clinical Oncology vol. 42 , ( 4_suppl ) 534 - 534 .

Jovaisaite A, Serrano M, Jackson-Spence F, Young M, Toms C, Wang Y, Nally E, Szabados B et al. ( 2023 ) . Immune-related adverse events after ≥12 months of starting immune checkpoint inhibitors . Journal of Clinical Oncology vol. 41 , ( 16_suppl ) e24086 - e24086 .

Nally E, Galazi M, Smallcombe N, Mills H, Ricketts W, Nally E ( 2021 ) . Improving the educational value of the multi-disciplinary team (MDT) meeting . Conference: Medical education, web and internet

Jackson-Spence FE, Ackerman C, Khan M, Grant M, Soosaipillai G, Nally E, Choy J, Powles TB et al. ( 2021 ) . P0461 The role of angiogenic signatures in advanced urothelial carcinoma (aUC) treated with VEGF-targeted therapy . European Urology vol. 79 ,

Nally E ( 2014 ) . Itching for a solution: how topical steroids became a standard treatment for eczema . Pharmaceutical historian vol. 44 , ( 3 ) 56 - 64 .